Goodsurance

Drug prices & Part D

Medicare Part D Deductible Rises to 700 Dollars and Out-of-Pocket Drug Cap Reaches 2,400 Dollars for 2027

The Inflation Reduction Act tied the Medicare Part D annual deductible and catastrophic spending limit to drug cost growth, and both parameters rise again for 2027, continuing an upward pattern as specialty and GLP-1 drug spending climbs across the program.

By the Goodsurance editorial teamAugust 4, 2026

The standard Medicare Part D drug plan deductible will rise to 700 dollars in 2027, up from 615 dollars in 2026, and the annual out-of-pocket spending cap will increase to 2,400 dollars from 2,100 dollars, according to the CMS 2027 Medicare Advantage and Part D Rate Announcement.

Both thresholds are set by a formula in the Inflation Reduction Act of 2022 that links the parameters to the annual growth rate of per-capita drug spending across the Part D program. Because program-wide drug spending has continued to rise, driven partly by the spread of high-cost specialty medications and GLP-1 drugs, both figures move upward each year.

At the same time, the IRA permanently eliminated the Medicare Part D coverage gap, known as the doughnut hole, beginning in 2025. Before that change, beneficiaries could face thousands of dollars in additional cost-sharing mid-year when their spending entered the gap. Now, the benefit moves through three phases: a deductible phase, an initial coverage phase, and a catastrophic phase in which the enrollee pays nothing more for covered drugs for the rest of the calendar year.

The IRA also limits the annual increase in the base Part D beneficiary premium to no more than 6 percent through 2029. CMS confirmed the 2027 base premium at 41 dollars and 33 cents in late July 2026.

For most Part D enrollees, reaching the 2,400-dollar threshold requires very high-cost medications. Those treating cancer, multiple sclerosis, or rheumatoid arthritis with specialty drugs are most likely to reach the catastrophic phase and benefit from the zero cost-share protection that follows.

In plain words

Medicare Part D helps pay for prescription drugs. In 2027, you will pay the first 700 dollars of drug costs yourself before Part D starts paying. This is called the deductible. It goes up from 615 dollars in 2026. There is also a yearly cap on drug costs. Once you reach 2,400 dollars in covered drug spending in 2027, you pay nothing more for covered drugs that year. The cap was 2,100 dollars in 2026. Both numbers rise each year based on how much drug costs grow across the program. The old coverage gap, which used to add costs mid-year, is permanently gone under the 2022 law.

Source: CMS
Read at the source →

More news

Other stories on what is moving in Medicare.

Drug prices & Part D

KFF: Medicare Advantage Drug Plans Received Over 600 Dollars Per Member in Rebates That Standalone Drug Plans Cannot Access

A KFF analysis explains the structural payment asymmetry that makes it harder for standalone Part D plans to compete on drug premiums, as the number of those plans hits record lows ahead of open enrollment.

August 8, 2026

Drug prices & Part D

Bipartisan Senate Bill Would Preserve Drug Discounts for Safety-Net Hospitals and Shut Down a Rebate Pilot

Six senators from both parties introduced the SUSTAIN 340B Act on August 5, proposing to protect point-of-purchase drug discounts for safety-net providers while adding new transparency and audit requirements.

August 6, 2026

Drug prices & Part D

CMS Counted a 2020 Reclassification Date for Creon, Delaying Medicare Price Talks by Years, Report Says

Public Citizen says CMS allowed AbbVie to use the date Creon was reclassified as a biologic rather than its original FDA approval date, pushing the drug's eligibility for Medicare price negotiation years into the future.

August 5, 2026

Drug prices & Part D

Medicare and Drug Manufacturers Are Holding Negotiation Meetings This Summer on 15 High-Cost Drugs, With Final Prices Due by November

The third cycle of Medicare drug price negotiations is in its most active phase, with CMS and participating manufacturers in sessions that must conclude by November 1, 2026, to set maximum fair prices on cancer, HIV, and other specialty drugs taking effect in 2028.

August 3, 2026

Drug prices & Part D

CMS Confirms the 2027 Medicare Part D Base Premium at 41 Dollars and 33 Cents as a Federal Stabilization Subsidy for Drug Plans Ends

The confirmed base premium equals the maximum 6 percent annual increase the Inflation Reduction Act allows, but consumer advocates warn that actual plan-level premiums, which are set above that floor, are likely to climb sharply once a temporary federal subsidy expires at year-end.

July 30, 2026

Drug prices & Part D

KFF: The Part D Subsidy Program Being Dropped Cost 9.8 Billion Dollars and Held Premiums Down for 24.9 Million Enrollees

A KFF analysis published after CMS's July 28 announcement tallies what the two-year Part D stabilization demonstration achieved, and describes the shrinking standalone drug plan market those enrollees will now navigate without that buffer.

July 29, 2026